Neoadjuvant/adjuvant/chemoprevention therapy and tumor downstaging

Hepatocellular Carcinoma

Volumn , Issue , 2008, Pages 709-737

  Lau, W Y ^a   Lai, Eric C H ^b  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 64949101165     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812770059_0032     Document Type: Chapter

References (94)

1. Lau WY (2000). Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y (eds.), Surgery of the Liver and Biliary Tract, Vol. 2, WB Saunders, London, England, pp. 1423-50.
2. Lai EC, Lau WY (2005). The continuing challenge of hepatic cancer in Asia. Surgeon 3:210-5.
3. Lau WY (2002). Management of hepatocellular carcinoma. JR Coll Surg Edinb47:389-99.
4. Shi M, Zhang CQ, Zhang YQ, et al. (2004). Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. WorldJ Surg 28:376-81.
5. Wong IH, Yeo W, Leung T, et al. (2001). Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167:183-91.
6. Wong IH, Lau WY, Leung T, et al. (1999). Hematogenous dissemination of hepatocytes and tumor cells after surgical resection ofhepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5:4021-7.
7. Wong IH, Leung T, Ho S, et al. (1997). Semiquantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer 76:628-33.
8. Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatic malignancy - a strategy to increase resectability. Ann Surg Oncol (in press).
9. Lau WY, Leung TW, Yu SC, Ho SK (2003). Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237:171-9.
10. Lau WY, Yu SC, Lai EC, Leung TW (2006). Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 202:155-68.
11. Lau WY, Leung TW, Lai BS, et al. (2001). Preoperative systemic chemoim-munotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 233:236-41.
12. Lau WY, Ho SK, Yu SC, et al. (2004). Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240:299-305.
13. Chan ES, Chow PK, Tai B, et al. (2000). Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev: CD001199.
14. Schwartz JD, Schwartz M, Mandeli J, Sung M (2002). Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3:593-603.
15. Nagasue N, Galizia G, Kohno H, et al. (1989). Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 106:81-6.
16. Adachi E, Matsumata T, Nishizaki T, et al. (1993). Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer72:3593-8.
17. Uchida M, Kohno H, Kubota H, et al. (1996). Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 20:326-31.
18. Luo YQ, Wang Y, Chen H, Wu MC (2002). Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 1:523-6.
19. Sasaki A, Iwashita Y, Shibata K, et al. (2006). Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32:773-9.
20. Wu CC, Ho YZ, Ho WL, et al. (1995). Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82:122-6.
21. Harada T, Matsuo K, Inoue T, et al. (1996). Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 224:4-9.
22. Majno PE, Adam R, Bismuth H, et al. (1997). Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688-701.
23. Paye F, Jagot P Vilgrain V, et al. (1998). Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. Arch Surg 133:767-72.
24. Di Carlo V, Ferrari G, Castoldi R, et al. (1998). Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology45:1950-4.
25. Gerunda GE, Neri D, Merenda R, et al. (2000). Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl 6:619-26.
26. Zhang Z, Liu Q, He J, ii al. (2000). The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89:2606-12.
27. Sugo H, Futagawa S, Beppu T, et al. (2003). Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg27:1295-9.
28. Yamasaki S, Hasegawa H, Kinoshita H, et al. (1996). A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87:206-11.
29. Asahara T, Itamoto T, Katayama K, et al. (1999). Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma - results of long-term follow-up. Hepatogastroenterology 46:1042-8.
30. Nakashima K, Kitano S, Kim YI, et al. (1996). Postoperative adjuvant arterial infusion chemotherapy for patients with hepatocellular carcinoma. Hepatogas-troenterology 43:1410-4.
31. Tanaka K, Shimada H, Togo S, et al. (1999). Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 46:1083-8.
32. Shimoda M, Bando T, Nagata T, et al. (2001). Prophylactic chemolipiodoliza-tion for postoperative hepatoma patients. Hepatogastroenterology 48:493-7.
33. Niguma T, Mimura T, Tutui N (2005). Adjuvant arterial infusion chemotherapy after resection ofhepatocellular carcinoma with portal thrombosis: a pilot study. J Hepatobiliary Pancreat Surg 12:249-53.
34. Ren ZG, Lin ZY, Xia JL, et al. (2004). Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol10:2791-4.
35. Cheng HY, Wang X, Chen D, et al. (2005). The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol 11:3644-6.
36. Izumi R, Shimizu K, Iyobe T, et al. (1994). Postoperative adjuvant hepatic arterial infusion oflipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20:295-301.
37. Li JQ, Zhang YQ, Zhang WZ, et al. (1995). Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 121:364-6.
38. Ono T, Nagasue N, Kohno H, et al. (1997). Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 24(Suppl):S6-18-S6-25.
39. Lai EC, Lo CM, Fan ST, et al. (1998). Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183-8.
40. Ueno S, Tanabe G, Yoshida A, et al. (1999). Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 86:248-54.
41. Ono T, Yamanoi A, Nazmy El Assal O, et al. (2001). Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91:2378-85.
42. Lygidakis NJ, Tsiliakos S (1996). Multidisciplinary management of hepatocellular carcinoma. Hepatogastroenterology 43:1611-9.
43. Yamamoto M, Arii S, Sugahara K, Tobe T (1996). Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br JSurg 83:336-40.
44. Lau WY (2000). Radiotherapy with emphasis on radioembolization for liver tumors. In: Blumgart LH, Fong Y (eds.), Surgery of the Liver and Biliary Tract, Vol. II, WB Saunders, London, England, pp. 1545-64.
45. Lau WY, Leung TW, Ho SK, et al. (1999). Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797-801.
46. Partensky C, Sassolas G, Henry L, et al. (2000). Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 135:1298-300.
47. Boucher E, Corbinais S, Rolland Y, et al. (2003). Adjuvant intra-arterial injection ofiodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237-41.
48. Ikeda K, Arase Y, Saitoh S, et al. (2000). Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-32.
49. Kubo S, Nishiguchi S, Hirohashi K, et al. (2002). Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418-22.
50. Sun HC, Tang ZY, Wang L, et al. (2006). Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132:458-65.
51. Takayama T, Sekine T, Makuuchi M, et al. (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802-7.
52. Kuang M, Peng BG, Lu MD, et al. (2004). Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10:1574-9.
53. Peng BG, Liang LJ, He Q, et al. (2005). Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 11:700-4.
54. Muto Y, Moriwaki H, Ninomiya M, et al. (1996). Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561-7.
55. 2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106:867-72.
56. Mazzaferro V, Regalia E, Doci R, et al. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-9.
57. Figueras J, Ibanez L, Ramos E, et al. (2001). Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 7:877-83.
58. Llovet JM, Fuster J, Bruix J (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434-40.
59. Maddala YK, Stadheim L, Andrews JC, et al. (2004). Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10:449-55.
60. Yao FY, Bass NM, Ascher NL, Roberts JP (2004). Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of EndStage Liver Disease (MELD) organ allocation policy. Liver Transpl 10:621-30.
61. Lubienski A (2005). Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 80(Suppl):S113-9.
62. Richard 3rd HM, Silberzweig JE, Mitty HA, et al. (2000). Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 214:775-9.
63. Venook AP, Ferrell LD, Roberts JP et al. (1995). Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg 1:242-8.
64. Harnois DM, Steers J, Andrews JC, et al. (1999). Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 5:192-9.
65. Graziadei IW, Sandmueller H, Waldenberger P, et al. (2003). Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557-63.
66. Oldhafer KJ, Chavan A, FruhaufNR, etal. (1998). Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 29:953-9.
67. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. (2005). Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 11:767-75.
68. Perez Saborido B, Meneu JC, Moreno E, et al. (2005). Is transarterial chemoem-bolization necessary before liver transplantation for hepatocellular carcinoma?Am J Surg 190:383-7.
69. Lencioni R, Della Pina C, Bartolozzi C (2005). Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 30:401-8.
70. Chen MS, Li JQ, Zheng Y, et al. (2006). A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321-8.
71. Lencioni RA, Allgaier HP, Cioni D, et al. (2003). Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235-40.
72. Llovet JM, Vilana R, Bru C, et al.; Barcelona Clinic Liver Cancer (BCLC) Group (2001). Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33:1124-9.
73. de BaereT, Risse O, Kuoch V, et al. (2003). Adverse events during radiofrequency treatment of 582 hepatic tumors. AJRAm J Roentgenol 181:695-700.
74. Livraghi T, Lazzaroni S, Meloni F, Solbiati L (2005). Risk of tumor seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg92:856-8.
75. Fontana RJ, Hamidullah H, Nghiem H, et al. (2002). Percutaneous radiofrequency thermal ablation ofhepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl 8:1165-74.
76. Johnson EW, Holck PS, Levy AE, et al. (2004). The role of tumor ablation in bridging patients to liver transplantation. Arch Surg 139:825-9.
77. Llovet JM, Mas X, Aponte JJ, et al. (2002). Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50:123-8.
78. Castroagudin JF, Delgado M, Villanueva A, et al. (2005). Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc 37:3871-3.
79. Lu DS, Yu NC, Raman SS, et al. (2005). Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41:1130-7.
80. Lu DS, Yu NC, Raman SS, et al. (2005). Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234:954-60.
81. Mazzaferro V, Battiston C, Perrone S, et al. (2004). Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 240:900-9.
82. Pompili M, Mirante VG, Rondinara G, et al. (2005). Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 11:1117-26.
83. Bartolozzi C, Lencioni R, Caramella D, et al. (1995). Treatment oflarge HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology197:812-8.
84. Koda M, Murawaki Y, Mitsuda A, et al. (2001). Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92:1516-24.
85. Troisi R, Defreyne L, Hesse UJ, et al. (1998). Multimodal treatment for hepatocellular carcinoma on cirrhosis: the role of chemoembolization and alcoholization before liver transplantation. Clin Transplant 12:313-9.
86. Fisher RA, Maluf D, Cotterell AH, et al. (2004). Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 18:502-12.
87. Chui AK, Rao AR, Island ER, et al. (2004). Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. Transplant Proc 36:2287-8.
88. Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al. (2005). Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 5:788-94.
89. Soderdahl G, Backman L, Isoniemi H, et al. (2006). A prospective, randomized, multi-center trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int19:288-94.
90. Sitzmann JV, Abrams R (1993). Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 217:149-54.
91. Fan J, Tang ZY, Yu YQ, et al. (1998). Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 15:674-8.
92. Meric F, Patt YZ, Curley SA, et al. (2000). Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7:490-5.
93. Clavien PA, Selzner N, Morse M, et al. (2002). Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 131:433-42.
94. Tang ZY, Zhou XD, Ma ZC, et al. (2004). Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 3:495-8.